Macular Edema Due to Retinal Vein Occlusion

Disease

Related News

Multiple Lucentis Biosimilars Advance Through FDA: Two Approvals Secured, One Pending Review

Jun 05, 2026

Two new interchangeable Lucentis biosimilars — Lupin's Ranluspec and Formycon/Bioeq's Nufymco — have received FDA approval, while Xbrane's Lucamzi is under review with an October target date. The Lucentis global market was valued at $630 million in 2024.

FDA approves updated Vabysmo label for macular edema following RVO beyond six months

Apr 14, 2026

The FDA approved an updated Vabysmo label for macular edema following retinal vein occlusion beyond six months. The decision extends treatment based on data showing visual acuity gains and central subfield thickness reductions maintained through week 72.